Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
KesimptaⓇ launch accelerating
Clinical differentiation further enhanced by favorable vaccination data
Sales evolution
USD m, % cc
66
99
50
50
FY: 372m
147
109
Launch
progress
14
Q4
2020
Q1
Q2
Q3
Q4
Clinical
progress
2021
CEZ
K Kesimpta L
Strong US sales despite COVID impacting the
dynamic segment (market NBRx -12% QoQ)
Strong access, increased demand based
on compelling benefit-risk
NBRx share 13.7%1, prescriber base +11%
>8,000 people living with MS treated in US,
majority naive or first switch
Ex-US: 63 global approvals incl. China, Japan
Reassuring data in COVID vaccinated patients
(ALITHIOS)²
1. Unadjusted share Q4. Data on file.
2. Cross AH, Delgado S, Habek M, et al. Outcomes of COVID-19 in Patients With Relapsing Multiple Sclerosis Receiving Ofatumumab: Data From the ALITHIOS Study and Post Marketing Surveillance:
37th Congress of ECTRIMS, October 13-15, 2021. Data on file from ALITHIOS, data cut off Sept 25th, 2021.
29 Investor Relations | Q4 2021 Results
1 NOVARTIS | Reimagining MedicineView entire presentation